Tie Zhou
Zhongquan Sun
Qinggui Meng
Dalin He
Guowei Shi
Jie Jin
Weibing Sun
Lijun Chen
Ben Liu
Jingen Wang
Jiwen Cheng
Zhiquan Hu
Yong Yang
Xishuang Song
Yinhuai Wang
Cheng Fu
Qiaoxia Zhou
Youzhi Tong
Ying-Hao Sun
Shanghai Renji Hospital, Shanghai, China
Fudan University Shanghai Cancer Center, Shanghai, China
Shanghai Renji Hospital, Shanghai, China
Guangxi Zhuang Autonomous Region Tumor Hospital, Nanning, China
First Affiliated Hospital of Xi-An Jiaotong University, Xi an, China
Shanghai Fifth People's Hospital,Fudan University, Shanghai, China
Peking University People's Hospital, Beijing, China
Second Affiliated Hospital of Dalian Medical University, Dalian, China
The Fifth Medical Center of the Chinese Peoples Liberation Army (PLA) General Hospital, Beijing, China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Jiangxi Provincial Peoples Hospital, Nanchang, China
Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Beijing Sanhuan Cancer Hospital, Beijing, China
Second Affiliated Hospital of Dalian Medical University, Dalian, China
Xiangya Hospital Central South University, Changsha, China
Liaoning Provincial Tumor Hospital, Shenyang, China
Kintor Pharmaceutical Limited, Suzhou, China
China
N/A
Oncology (ONC)
Urology
Metastatic castration-resistant prostate cancer
Prostate specific antigen
Enzalutamide
CB-7598
Docetaxel
GT0918
N/A
Randomized
Open Label
Multicenteric
II
N/A
N/A
N/A